Isospec Analytics is a Swiss life sciences startup commercialising molecular analysis technologies that can identify unknown molecules in minutes. The company is working to expand molecular analysis—already used in food and agritech—specifically for therapeutic and diagnostic applications to enable biomarker discovery and safer product development. Its platform is based on more than 20 years of research and combines analytical chemistry, photonics, and cryogenic materials originally designed for space applications to generate a new data dimension about molecular structures. Identifying unknown molecules addresses limitations of mass analysis by adding sensitivity and structural-identification capability for trace by-products and impurities. The founders — Ahmed Ben Faleh, Stephan Warnke, and Thomas Rizzo — formed the company in 2022 to redefine molecular analysis and unlock the 95% unknown molecular space in biological samples. Financially, Isospec recently closed a $1.9M Pre-Seed round to support its commercialisation and R&D efforts. IsoSpec Analytics is an EPFL spin-off that has developed a patented infrared fingerprinting technology combined with proprietary machine-learning tools to identify analytes and determine definitive molecular structure. The company introduces a new metric that combines detection sensitivity with unambiguous molecular identification to accelerate biotech product development and biomarker discovery. Initially IsoSpec will offer advanced analytical services while it builds a user-friendly platform for pharmaceutical and medical laboratories and automates molecular identification processes. The startup aims to apply its technology across drug development—particularly oncology and neurodegenerative disease biomarker discovery—as well as in early disease diagnostics, food tech, and agricultural science. The founding team (CTO Stephan Warnke, scientific advisor Prof. Thomas Rizzo, and CEO Ahmed Ben Faleh) has collaborated for six years and has already onboarded its first paying customers and is running pilot projects with firms ranging from biotech startups to multinational pharmaceutical and clinical nutrition companies. The company cites a total addressable market of USD 8.5 billion for characterizing regulated products and expects additional demand growth.

Total raised

$2M

Funding rounds

2

Latest round

Seed

Latest activity

Apr 2024